Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2768Triple Negative Breast Neoplasms 406Neoplasm Metastasis 156Breast Neoplasms, Male 102Neoplasms 100Ovarian Neoplasms 69Carcinoma, Non-Small-Cell Lung 68Carcinoma, Intraductal, Noninfiltrating 68Lung Neoplasms 66Brain Neoplasms 60Colorectal Neoplasms 52Inflammatory Breast Neoplasms 50Advanced Breast Cancer 49Breast Carcinoma In Situ 47Prostatic Neoplasms 42Melanoma 38Pancreatic Neoplasms 37Stomach Neoplasms 32Uterine Cervical Neoplasms 28Sarcoma 27HER2-positive Breast Cancer 27Endometrial Neoplasms 25Head and Neck Neoplasms 24Recurrence 23Colonic Neoplasms 22Carcinoma, Renal Cell 21Carcinoma, Ovarian Epithelial 21Small Cell Lung Carcinoma 20Multiple Myeloma 20Carcinoma, Ductal, Breast 20

Interventions

bazedoxifene 1Tamoxifen 1Estrogens, Conjugated (USP) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Risk Reduction Behavior × Breast × Clear all
NCT04821141 2025-10-29

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

Phase 2 Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Hot Flashes, Risk Reduction Behavior

NCT03346200 2025-03-07

KARISMA2

Karolinska Institutet

Phase 2 Completed
1,440 enrolled 14 charts
Breast

Breast Neoplasms, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡